Ramkumar Subramanian

1.1k total citations
58 papers, 894 citations indexed

About

Ramkumar Subramanian is a scholar working on Molecular Biology, Electrical and Electronic Engineering and Pharmacology. According to data from OpenAlex, Ramkumar Subramanian has authored 58 papers receiving a total of 894 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 15 papers in Electrical and Electronic Engineering and 13 papers in Pharmacology. Recurrent topics in Ramkumar Subramanian's work include Cholinesterase and Neurodegenerative Diseases (13 papers), Receptor Mechanisms and Signaling (13 papers) and Advancements in Photolithography Techniques (8 papers). Ramkumar Subramanian is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (13 papers), Receptor Mechanisms and Signaling (13 papers) and Advancements in Photolithography Techniques (8 papers). Ramkumar Subramanian collaborates with scholars based in India, United States and Taiwan. Ramkumar Subramanian's co-authors include Carl T. Lira, Bharath Rangarajan, Vishva Ray, Seong Jin Koh, David Shan‐Hill Wong, Chung Sung Tan, Matthias Orth, Choong-Un Kim, Ramakrishna Nirogi and Anil Shinde and has published in prestigious journals such as Nature Communications, Nano Letters and Nature Nanotechnology.

In The Last Decade

Ramkumar Subramanian

54 papers receiving 865 citations

Peers

Countries citing papers authored by Ramkumar Subramanian

Since Specialization

Citations

This map shows the geographic impact of Ramkumar Subramanian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ramkumar Subramanian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ramkumar Subramanian more than expected).

Fields of papers citing papers by Ramkumar Subramanian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ramkumar Subramanian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ramkumar Subramanian. The network helps show where Ramkumar Subramanian may publish in the future.

Co-authorship network of co-authors of Ramkumar Subramanian

This figure shows the co-authorship network connecting the top 25 collaborators of Ramkumar Subramanian. A scholar is included among the top collaborators of Ramkumar Subramanian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ramkumar Subramanian. Ramkumar Subramanian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deep learning-based pneumonia classifier on chest X-ray images 2024 ·AIP conference proceedings ·Ramkumar Subramanian, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Abid Ishaq, Sanjeevikumar Padmanaban	3
2	Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy 2024 ·Sleep Medicine ·Ramakrishna Nirogi, Anil Shinde, Vinod Goyal, (unknown), Vijay Benade, (unknown), (unknown), Ramkumar Subramanian, Veera Raghava Chowdary Palacharla, (unknown), Renny Abraham, (unknown), (unknown), Pradeep Jayarajan, (unknown), Richard Bogan	1
3	0051 Samelisant, a H3 Receptor Inverse Agonist for the Potential Treatment of Excessive Daytime Sleepiness in Parkinson’s Disease 2023 ·SLEEP ·Ramakrishna Nirogi, Vijay Benade, Renny Abraham, (unknown), (unknown), (unknown), (unknown), (unknown), Ramkumar Subramanian	1
4	Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling 2023 ·European Journal of Pharmacology ·Ramakrishna Nirogi, (unknown), (unknown), (unknown), Renny Abraham, (unknown), Veera Raghava Chowdary Palacharla, (unknown), (unknown), Ramkumar Subramanian, (unknown), (unknown), Vijay Benade, Pradeep Jayarajan, (unknown)	3
5	Masupirdine (SUVN‐502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type: Preliminary Efficacy and Phase‐3 Study Design 2023 ·Alzheimer s & Dementia ·Ramakrishna Nirogi, Renny Abraham, (unknown), (unknown), Vijay Benade, Anil Shinde, Mohammed Abdul Rasheed, (unknown), Vinod Goyal, Veera Raghava Chowdary Palacharla, Ramkumar Subramanian, Pradeep Jayarajan	0
6	Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization 2022 ·Psychopharmacology ·Ramakrishna Nirogi, Renny Abraham, Pradeep Jayarajan, (unknown), (unknown), (unknown), (unknown), Vinod Goyal, (unknown), Ramkumar Subramanian, (unknown), (unknown), Veera Raghava Chowdary Palacharla, (unknown), (unknown), (unknown)	5
7	Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study 2022 ·Neurology and Therapy ·Ramakrishna Nirogi, Vinod Goyal, Vijay Benade, Ramkumar Subramanian, (unknown), (unknown), Anil Shinde, (unknown), Pradeep Jayarajan, (unknown), Jeffrey L. Cummings	5
8	Multimodal NASH prognosis using 3D imaging flow cytometry and artificial intelligence to characterize liver cells 2022 ·Scientific Reports ·Ramkumar Subramanian, Rui Tang, (unknown), (unknown), Jeffrey N. Miner, Yu‐Hwa Lo	4
9	Potential benefits of Masupirdine (SUVN-502) on Behavioral and Psychological symptoms in patients with moderate Alzheimer’s Disease (5090) 2020 ·Neurology ·Ramakrishna Nirogi, Anil Shinde, Pradeep Jayarajan, Vinod Goyal, (unknown), Ramkumar Subramanian, (unknown), (unknown), (unknown)	3
10	Masupirdine (SUVN‐502) in combination with donepezil and memantine in moderate Alzheimer's disease: Effect of AD duration since diagnosis and patient’s age on efficacy endpoints 2020 ·Alzheimer s & Dementia ·Ramakrishna Nirogi, Anil Shinde, Vijay Benade, Ramkumar Subramanian, Gopinadh Bhyrapuneni, (unknown), (unknown), Mohammed Abdul Rasheed, (unknown), (unknown)	1
11	0054 SUVN-G3031, a Histamine H3 Receptor Inverse Agonist Produces Wake Promoting Effect in Orexin-2-saporin Lesioned Rats 2019 ·SLEEP ·Vijay Benade, (unknown), (unknown), Ramkumar Subramanian, (unknown), (unknown), Ramakrishna Nirogi	3
12	Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H₃ Receptor Inverse Agonist with Robust Wake-Promoting Activity 2019 ·Journal of Medicinal Chemistry ·Ramakrishna Nirogi, Anil Shinde, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ramkumar Subramanian, Vijay Benade, Veera Raghava Chowdary Palacharla, Pradeep Jayarajan, (unknown), (unknown)	17
13	SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization 2018 ·Behavioural Pharmacology ·Ramakrishna Nirogi, Renny Abraham, Vijay Benade, (unknown), Pradeep Jayarajan, Gopinadh Bhyrapuneni, Nageswararao Muddana, (unknown), Ramkumar Subramanian, Anil Shinde, (unknown), (unknown)	30
14	Transient Induced Molecular Electronic Spectroscopy (TIMES) for study of protein-ligand interactions 2016 ·Scientific Reports ·Tiantian Zhang, Ti‐Hsuan Ku, Yuanyuan Han, Ramkumar Subramanian, (unknown), (unknown), (unknown), Jian‐Jang Huang, Yu‐Hwa Lo	4
15	P3‐016: SUVN‐D4010, A Potent and Selective 5‐HT₄ Receptor Partial Agonist: Safety, Tolerability and Pharmacokinetics in Humans 2016 ·Alzheimer s & Dementia ·Pradeep Jayarajan, Gopinadh Bhyrapuneni, Koteshwara Mudigonda, (unknown), Nageswararao Muddana, Veera Raghava Chowdary Palacharla, Vijay Benade, Renny Abraham, Ramkumar Subramanian, Vinod Goyal, (unknown), (unknown), (unknown), Mohammed Abdul Rasheed, Ramakrishna Nirogi	3
16	Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease 2015 ·European Journal of Medicinal Chemistry ·Ramakrishna Nirogi, (unknown), Anil Shinde, (unknown), (unknown), (unknown), (unknown), Gopinadh Bhyrapuneni, (unknown), Vijay Benade, Veera Raghava Chowdary Palacharla, Pradeep Jayarajan, Ramkumar Subramanian, Vinod Goyal	46
17	Benzamide derivatives and their constrained analogs as histamine H 3 receptor antagonists 2015 ·European Journal of Medicinal Chemistry ·Ramakrishna Nirogi, Anil Shinde, (unknown), (unknown), (unknown), (unknown), (unknown), Ramkumar Subramanian, (unknown), Gopinadh Bhyrapuneni, Renny Abraham	4
18	Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT₆Receptor Antagonists 2012 ·Journal of Medicinal Chemistry ·Ramakrishna Nirogi, Anil Shinde, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ramkumar Subramanian, Gopinadh Bhyrapuneni, Nageswararao Muddana, Pradeep Jayarajan	13
19	CMOS-compatible fabrication of room-temperature single-electron devices 2008 ·Nature Nanotechnology ·Vishva Ray, Ramkumar Subramanian, (unknown), (unknown), Choong-Un Kim, Seong Jin Koh	68
20	Effect of real masks on wafer patterning 2000 ·Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE ·(unknown), Ramkumar Subramanian, David H.‐F. Teng, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact